Technologieangebote

Novel Markers for Improved Diagnosis of Rheumatoid Arthritis

The combined use of RFs with the anti-cyclic citrullinated peptide (anti-CCP) or assays resulted in detection levels of about 40% of early arthritis patients and 70-80% of established RA patients.

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Ursula Haufe

Kommentare (0)

Schreiben Sie einen Kommentar